منابع مشابه
Expanded guidelines for use of varicella-zoster immune globulin.
Zoster immune globulin (ZIG) can prevent clinical chickenpox in exposed, susceptible, normal chilthen.’ In a collaborative study2 in which 15 susceptible children at high risk received ZIG within three days following exposure, there were no deaths and only one child developed progressive vanicella. At that time, a mortality of 7% and a rate of progressive varicella of 30% were reported in simil...
متن کاملCongenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin.
A 33-year-old woman who was engaged to be married presented for her initial visit with an obstetrician. Her varicella-zoster IgG antibody titer, as measured by latex agglutination, was < 0.91, which signified nonimmunity. The patient did not know if she had previously had varicella. She had not been vaccinated. Three months later, she became pregnant. She was told to avoid crowds of children an...
متن کاملImmune Globulin Therapy
Intravenous immunoglobulin (IVIg) therapy may be considered medically necessary for the following indications. Immunodeficiency States—patients with Primary Immunodeficiencies, including o Congenital agammaglobulinemia o Hypogammaglobulinemia o Common variable immunodeficiency o Severe combined immunodeficiency (SCID) o Wiskott-Aldrich syndrome o X-linked agammaglobulinemia (Bruton agammaglob...
متن کاملImmune Globulin Therapy
©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 34 Applies to all products admin...
متن کاملImmune Globulin Subcutaneous (Human) 20%
Immune globulin subcutaneous 20% is a new high-concentration (200 g/L) solution of highly purified human IgG (≥98%) indicated in the EU and the US for antibody replacement therapy in patients with primary immunodeficiency with antibody deficiency, and in the EU for replacement therapy in humoral immunodeficiency secondary to myeloma or chronic lymphocytic leukaemia. Immune globulin subcutaneous...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Research
سال: 1970
ISSN: 0031-3998,1530-0447
DOI: 10.1203/00006450-197009000-00112